Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.33 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4525399 | 0.99 | ALDH1A1 (0.42) | CYP1A2CYP2C9ALDH1A1LMNAKDM4E | |
| SCHEMBL4516107 | 0.87 | ALDH1A1 (0.42) | CYP2C9ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL4525396 | 0.85 | ALDH1A1 (0.43) | CYP2C9ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL16592456 | 0.79 | CYP1A2 (0.43) | CYP1A2CYP2C9ALDH1A1LMNAKDM4E | |
| Tetraethylene Glycol SCHEMBL3062384 | 0.77 | ALDH1A1 (0.49) | CYP1A2CYP2C9ALDH1A1LMNAKDM4E | |
| Hexaethylene Glycol SCHEMBL11280667 | 0.77 | ALDH1A1 (0.49) | CYP1A2CYP2C9ALDH1A1LMNAKDM4E | |
| SCHEMBL11674046 | 0.77 | ALDH1A1 (0.49) | CYP1A2CYP2C9ALDH1A1LMNAKDM4E | |
| Triethylene Glycol SCHEMBL6130636 | 0.77 | ALDH1A1 (0.49) | CYP1A2CYP2C9ALDH1A1LMNAKDM4E | |
| Tetraethylene Glycol SCHEMBL1145155 | 0.77 | ALDH1A1 (0.49) | CYP1A2CYP2C9ALDH1A1LMNAKDM4E | |
| Hexaethylene Glycol SCHEMBL4379136 | 0.77 | ALDH1A1 (0.49) | CYP1A2CYP2C9ALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099044-A1 | Nanoparticles and Method to Control Nanoparticle Spacing | OREGON, UNIVERSITY OF | 2009-04-16 | — | — | US | disclosed |
| WO-2006127675-A2 | NANOPARTICLES AND METHOD TO CONTROL NANOPARTICLE SPACING | STATE OF OREGON ACTING BY & THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099044-A1 | Nanoparticles and Method to Control Nanoparticle Spacing | ICAM1, L1CAM, EPCAM | EGFR 1524/4885ERBB2 2452/4885CYP1A2 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.